GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » EBITDA per Share

Benitec Biopharma (Benitec Biopharma) EBITDA per Share : $-9.70 (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma EBITDA per Share?

Benitec Biopharma's EBITDA per Share for the three months ended in Mar. 2024 was $-1.60. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.70.

During the past 3 years, the average EBITDA per Share Growth Rate was -21.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Benitec Biopharma's EBITDA per Share or its related term are showing as below:

BNTC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21   Med: 22.95   Max: 58.5
Current: -21

During the past 11 years, the highest 3-Year average EBITDA per Share Growth Rate of Benitec Biopharma was 58.50% per year. The lowest was -21.00% per year. And the median was 22.95% per year.

BNTC's 3-Year EBITDA Growth Rate is ranked worse than
76.51% of 1290 companies
in the Biotechnology industry
Industry Median: 6.3 vs BNTC: -21.00

Benitec Biopharma's EBITDA for the three months ended in Mar. 2024 was $-4.19 Mil.

During the past 3 years, the average EBITDA Growth Rate was -34.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 11 years, the highest 3-Year average EBITDA Growth Rate of Benitec Biopharma was 26.10% per year. The lowest was -34.30% per year. And the median was -19.85% per year.


Benitec Biopharma EBITDA per Share Historical Data

The historical data trend for Benitec Biopharma's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma EBITDA per Share Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.82 -131.78 -53.17 -635.14 -233.51

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.78 -2.72 -2.61 -1.60

Benitec Biopharma EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Benitec Biopharma's EBITDA per Share for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA per Share(A: Jun. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-19.148/0.082
=-233.51

Benitec Biopharma's EBITDA per Share for the quarter that ended in Mar. 2024 is calculated as

EBITDA per Share(Q: Mar. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-4.185/2.616
=-1.60

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma  (NAS:BNTC) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Benitec Biopharma EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000